Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis.
Butzkueven H, Hillert J, Soilu-Hänninen M, Ziemssen T, Kuhle J, Wergeland S, Magyari M, Berger JR, Moore N, Aydemir A, Bezemer I, Sabidó M. Butzkueven H, et al. Among authors: sabido m. Curr Med Res Opin. 2023 Oct;39(10):1367-1374. doi: 10.1080/03007995.2023.2256220. Epub 2023 Sep 7. Curr Med Res Opin. 2023. PMID: 37675878 Free article.
Improving Data Collection in Pregnancy Safety Studies: Towards Standardisation of Data Elements in Pregnancy Reports from Public and Private Partners, A Contribution from the ConcePTION Project.
Favre G, Richardson JL, Moore A, Geissbühler Y, Jehl V, Oliver A, Shechtman S, Diav-Citrin O, Berlin M, De Haan T, Baud D, Panchaud A, Mor A, Sabidó M, de Souza S, Chambers C, van Rijt-Weetink YRJ, van Puijenbroek EP, Yates LM, Girardin F, Stellfeld M, Winterfeld U. Favre G, et al. Among authors: sabido m. Drug Saf. 2024 Mar;47(3):227-236. doi: 10.1007/s40264-023-01384-3. Epub 2023 Dec 19. Drug Saf. 2024. PMID: 38114757 Free PMC article.
Introducing a core dataset for real-world data in multiple sclerosis registries and cohorts: Recommendations from a global task force.
Parciak T, Geys L, Helme A, van der Mei I, Hillert J, Schmidt H, Salter A, Zakaria M, Middleton R, Stahmann A, Dobay P, Hernandez Martinez-Lapiscina E, Iaffaldano P, Plueschke K, Rojas JI, Sabidó M, Magyari M, van der Walt A, Arickx F, Comi G, Peeters LM. Parciak T, et al. Among authors: sabido m. Mult Scler. 2024 Mar;30(3):396-418. doi: 10.1177/13524585231216004. Epub 2023 Dec 23. Mult Scler. 2024. PMID: 38140852 Free PMC article.
Harmonized Data Quality Indicators Maintain Data Quality in Long-Term Safety Studies Using Multiple Sclerosis Registries/Data Sources: Experience from the CLARION Study.
Hillert J, Butzkueven H, Magyari M, Wergeland S, Moore N, Soilu-Hänninen M, Ziemssen T, Kuhle J, Pontieri L, Forsberg L, Aarseth JH, Zhu C, Sicignano N, Mushnikov V, Bezemer I, Sabidó M. Hillert J, et al. Among authors: sabido m. Clin Epidemiol. 2024 Oct 17;16:717-732. doi: 10.2147/CLEP.S480525. eCollection 2024. Clin Epidemiol. 2024. PMID: 39435029 Free PMC article.
The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets.
Butzkueven H, Moore N, Aydemir A, Sõnajalg J, Bezemer I, Korhonen P, Sabidó M; CLARION Study Group. Butzkueven H, et al. Among authors: sabido m. Curr Med Res Opin. 2022 Jul;38(7):1167-1176. doi: 10.1080/03007995.2022.2059977. Epub 2022 Apr 28. Curr Med Res Opin. 2022. PMID: 35357268 Free article.
71 results